KR102061537B1 - Ｈｎｏ 공여체들로서의 하이드록실아민으로 치환된 멜드럼산, 바르비투르산 및 피라졸론 유도체들 - Google Patents

Ｈｎｏ 공여체들로서의 하이드록실아민으로 치환된 멜드럼산, 바르비투르산 및 피라졸론 유도체들 Download PDF

Info

Publication number
KR102061537B1
KR102061537B1 KR1020147013269A KR20147013269A KR102061537B1 KR 102061537 B1 KR102061537 B1 KR 102061537B1 KR 1020147013269 A KR1020147013269 A KR 1020147013269A KR 20147013269 A KR20147013269 A KR 20147013269A KR 102061537 B1 KR102061537 B1 KR 102061537B1
Authority
KR
South Korea
Prior art keywords
compound
alkyl
delete delete
disease
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147013269A
Other languages
English (en)
Korean (ko)
Other versions
KR20140107197A (ko
Inventor
존 피. 토스카노
데릴 에이. 구스리
Original Assignee
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티 filed Critical 더 존스 홉킨스 유니버시티
Publication of KR20140107197A publication Critical patent/KR20140107197A/ko
Application granted granted Critical
Publication of KR102061537B1 publication Critical patent/KR102061537B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147013269A 2011-10-17 2012-10-16 Ｈｎｏ 공여체들로서의 하이드록실아민으로 치환된 멜드럼산, 바르비투르산 및 피라졸론 유도체들 Expired - Fee Related KR102061537B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548036P 2011-10-17 2011-10-17
US61/548,036 2011-10-17
PCT/US2012/060425 WO2013059194A1 (en) 2011-10-17 2012-10-16 Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors

Publications (2)

Publication Number Publication Date
KR20140107197A KR20140107197A (ko) 2014-09-04
KR102061537B1 true KR102061537B1 (ko) 2020-01-03

Family

ID=47143299

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147013269A Expired - Fee Related KR102061537B1 (ko) 2011-10-17 2012-10-16 Ｈｎｏ 공여체들로서의 하이드록실아민으로 치환된 멜드럼산, 바르비투르산 및 피라졸론 유도체들

Country Status (13)

Country Link
US (3) US9181213B2 (https=)
EP (1) EP2776402B1 (https=)
JP (1) JP6177246B2 (https=)
KR (1) KR102061537B1 (https=)
CN (2) CN104053647B (https=)
AU (2) AU2013201929B2 (https=)
BR (1) BR112014009282B1 (https=)
CA (1) CA2852914C (https=)
HK (1) HK1200168A1 (https=)
IL (1) IL232101A (https=)
MX (1) MX363306B (https=)
SG (1) SG11201401587QA (https=)
WO (1) WO2013059194A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6177246B2 (ja) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
SG10201802862WA (en) 2013-01-18 2018-05-30 Cardioxyl Pharmaceuticals Inc Pharmaceutical compositions comprising nitroxyl donors
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
US9464061B2 (en) * 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US10583141B2 (en) 2015-06-26 2020-03-10 The Johns Hopkins University N-substituted hydroxamic acids with carbon-based leaving groups as efficient HNO donors and uses thereof
KR20180070672A (ko) 2015-10-19 2018-06-26 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여자로서의 n-히드록실술폰아미드 유도체
US10723704B2 (en) 2015-10-19 2020-07-28 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
EP3490975B1 (en) * 2016-07-28 2021-05-05 The Johns Hopkins University O-substituted hydroxamic acids
WO2018128999A1 (en) 2017-01-03 2018-07-12 Cardioxyl Pharmaceuticals, Inc. Method of administering nitroxyl donating compounds
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US11912647B2 (en) 2020-05-22 2024-02-27 University Of Georgia Research Foundation, Inc. Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109175A1 (en) 2006-03-17 2007-09-27 Johns Hopkins University School Of Medicine N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
AU741180B2 (en) 1997-10-24 2001-11-22 Shionogi & Co., Ltd. Antirheumatic
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
DE69924735T2 (de) 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2005074598A2 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
EP1846439A2 (en) 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
US20090298795A1 (en) 2005-06-23 2009-12-03 The Johns Hopins University Thiol-Sensitive Positive Inotropes
US7696373B2 (en) 2006-04-13 2010-04-13 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
CN104119310B (zh) 2007-09-26 2017-04-12 约翰斯霍普金斯大学 作为新的在生理学上可用于硝酰基供体的n‑羟基磺酰胺衍生物及包含其的医药组合物
EP3067352A3 (en) 2008-05-07 2016-10-19 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
US20110160200A1 (en) 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
AU2010328234B2 (en) 2009-12-07 2016-05-12 Cardioxyl Pharmaceuticals, Inc. N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
CN105130855B (zh) * 2009-12-07 2018-05-25 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物及其用途
JP6177246B2 (ja) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
SG10201802862WA (en) 2013-01-18 2018-05-30 Cardioxyl Pharmaceuticals Inc Pharmaceutical compositions comprising nitroxyl donors
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109175A1 (en) 2006-03-17 2007-09-27 Johns Hopkins University School Of Medicine N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

Also Published As

Publication number Publication date
EP2776402B1 (en) 2017-07-26
JP2015501308A (ja) 2015-01-15
JP6177246B2 (ja) 2017-08-09
AU2013201929A1 (en) 2013-05-02
SG11201401587QA (en) 2014-07-30
CN108409662A (zh) 2018-08-17
IL232101A (en) 2017-04-30
US9499511B2 (en) 2016-11-22
CN108409662B (zh) 2021-10-26
US9862699B2 (en) 2018-01-09
US20160115148A1 (en) 2016-04-28
KR20140107197A (ko) 2014-09-04
MX2014004596A (es) 2014-09-04
HK1200168A1 (en) 2015-07-31
US9181213B2 (en) 2015-11-10
BR112014009282A2 (pt) 2017-06-13
IL232101A0 (en) 2014-05-28
CN104053647B (zh) 2018-06-01
AU2013201929B2 (en) 2015-07-23
US20140275134A1 (en) 2014-09-18
AU2015246114A1 (en) 2015-11-12
CA2852914A1 (en) 2013-04-25
US20170050947A1 (en) 2017-02-23
WO2013059194A1 (en) 2013-04-25
EP2776402A1 (en) 2014-09-17
BR112014009282B1 (pt) 2021-12-14
MX363306B (es) 2019-03-20
BR112014009282A8 (pt) 2020-04-22
CA2852914C (en) 2019-11-26
CN104053647A (zh) 2014-09-17

Similar Documents

Publication Publication Date Title
KR102061537B1 (ko) Ｈｎｏ 공여체들로서의 하이드록실아민으로 치환된 멜드럼산, 바르비투르산 및 피라졸론 유도체들
US9458127B2 (en) Bis-acylated hydroxylamine derivatives
AU2016206369B2 (en) N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives
JP6192016B2 (ja) ニトロキシル供与体としての新規ニトロソ化合物およびその使用方法
WO2023133457A1 (en) Novel kalirin inhibitors for regulation of synaptic plasticity and neuropathic pain treatment
CN107304180A (zh) 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
HUP0001297A2 (hu) Karbociklussal és heterociklussal helyettesített szemikarbazon- és tioszemikarbazonszármazékok, valamint ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20221116

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20231227

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231227